These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 11590254)

  • 1. Dialysis: its role in optimizing recombinant erythropoietin treatment.
    Locatelli F; Del Vecchio L; Andrulli S
    Nephrol Dial Transplant; 2001; 16 Suppl 7():29-35. PubMed ID: 11590254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing dose and mode of renal replacement therapy in anaemia management.
    Locatelli F
    Nephrol Dial Transplant; 2002; 17 Suppl 5():60-5. PubMed ID: 12091610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dialysis adequacy and response to erythropoietic agents: what is the evidence base?
    Locatelli F; Del Vecchio L
    Nephrol Dial Transplant; 2003 Nov; 18 Suppl 8():viii29-35. PubMed ID: 14607998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of high-flux dialysis on the anaemia of haemodialysis patients.
    Locatelli F; Andrulli S; Pecchini F; Pedrini L; Agliata S; Lucchi L; Farina M; La Milia V; Grassi C; Borghi M; Redaelli B; Conte F; Ratto G; Cabiddu G; Grossi C; Modenese R
    Nephrol Dial Transplant; 2000 Sep; 15(9):1399-409. PubMed ID: 10978398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of acetate-free biofiltration on the anaemia of haemodialysis patients: a prospective cross-over study.
    Basile C; Giordano R; Montanaro A; De Maio PD; De Padova FD; Marangi AL; Semeraro A
    Nephrol Dial Transplant; 2001 Sep; 16(9):1914-9. PubMed ID: 11522879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyporesponsiveness to recombinant human erythropoietin.
    Drüeke T
    Nephrol Dial Transplant; 2001; 16 Suppl 7():25-8. PubMed ID: 11590253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of the response of elderly patients with end-stage renal disease to epoetin alfa or beta.
    Nicholas JC
    Drugs Aging; 2004; 21(3):187-201. PubMed ID: 14979736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epoetin (recombinant human erythropoietin). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis.
    Faulds D; Sorkin EM
    Drugs; 1989 Dec; 38(6):863-99. PubMed ID: 2693045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dialysis adequacy and response to erythropoiesis-stimulating agents: what is the evidence base?
    Locatelli F; Del Vecchio L; Pozzoni P; Andrulli S
    Semin Nephrol; 2006 Jul; 26(4):269-74. PubMed ID: 16949464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations.
    Collins AJ
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 2():ii2-6. PubMed ID: 12819293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients.
    Dunn CJ; Wagstaff AJ
    Drugs Aging; 1995 Aug; 7(2):131-56. PubMed ID: 7579784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Frequency of anaemia and indications for treatment with epoetin in chronic renal failure at the pre-dialysis stage].
    Jungers PY; Nguyen-Khoa T; Joly D; Choukroun G; Massy ZA; Jungers P
    Presse Med; 2003 Feb; 32(5):212-6. PubMed ID: 12610461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure.
    Dunn CJ; Markham A
    Drugs; 1996 Feb; 51(2):299-318. PubMed ID: 8808169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients.
    Cody J; Daly C; Campbell M; Donaldson C; Grant A; Khan I; Pennington S; Vale L; Wallace S; MacLeod A
    Cochrane Database Syst Rev; 2001; (4):CD003266. PubMed ID: 11687180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-volume online haemodiafiltration improves erythropoiesis-stimulating agent (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study.
    Panichi V; Scatena A; Rosati A; Giusti R; Ferro G; Malagnino E; Capitanini A; Piluso A; Conti P; Bernabini G; Migliori M; Caiani D; Tetta C; Casani A; Betti G; Pizzarelli F
    Nephrol Dial Transplant; 2015 Apr; 30(4):682-9. PubMed ID: 25385719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRE-dialysis survey on anaemia management.
    Valderrábano F; Hörl WH; Macdougall IC; Rossert J; Rutkowski B; Wauters JP
    Nephrol Dial Transplant; 2003 Jan; 18(1):89-100. PubMed ID: 12480965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partial correction of dialysis-associated anaemia does not reduce erythropoietin dose or the incidence of side effects.
    Mellotte GJ; Morgan SH; Smith SA; Bending MR; Eisinger AJ
    Nephron; 1993; 64(3):465-7. PubMed ID: 8341395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomic analysis of plasma proteins of high-flux haemodialysis and on-line haemodiafiltration patients reveals differences in transthyretin levels related with anaemia.
    Martínez-Alonso E; Alcázar P; Camafeita E; Fernández-Lucas M; Ruíz-Roso G; Alcázar A
    Sci Rep; 2020 Sep; 10(1):16029. PubMed ID: 32994444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload.
    Tarng DC; Huang TP
    Nephrol Dial Transplant; 1998 Nov; 13(11):2867-72. PubMed ID: 9829492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epoetin Beta: a review of its clinical use in the treatment of anaemia in patients with cancer.
    Cheer SM; Wagstaff AJ
    Drugs; 2004; 64(3):323-46. PubMed ID: 14871172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.